Navigation Links
Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology
Date:2/27/2009

Dressing Offers a Highly Effective and Affordable New Option to Help Combat the Escalating MRSA Crisis

PRINCETON, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that its first BIOGUARD Barrier Dressings have received clearance from the U.S. Food and Drug Administration for marketing and distribution. BIOGUARD will offer surgeons, wound care clinicians, infection control experts and primary care doctors a new weapon against the transmission of such virulent bacteria as Methicillin-resistant Staphylococcus aureus (MRSA). Coming on the heels of Derma Sciences' successful launch of its MEDIHONEY(TM) dressing line in 2008, BIOGUARD is the company's latest new product entrant into the $14 billion global wound care market. Sales of the dressings are expected to commence in June, 2009.

Speaking about the FDA clearance, Derma Sciences' CEO Ed Quilty stated, "This clearance represents a significant milestone for Derma Sciences and provides another large step in implementing our strategic plan. We believe that BIOGUARD, a cost-effective gauze-based dressing that has been shown to kill 99.999% of MRSA, will be a great asset to healthcare providers as they look for more effective and efficient ways to combat the transmission of virulent pathogens throughout their facilities. Surgical site infections are a serious concern, and with changes in reimbursement, prevention has become a major objective for hospitals." Quilty continued, "This gives our sales reps yet another novel wound care product to sell, and will help Derma Sciences reach our goal of profitability in a quicker timeframe. BIOGUARD will open many new doors for us, especially on the gauze side of the business, a large component of the $14 billion global wound care market."

The gauze-based line of dressings incorporates Quick-Med Technologies, Inc.'s patented NIMBUS(R) (Novel Intrinsically Micro Bonded Utility Substrate) cationic biocide technology, licensed by Derma Sciences in 2007. This represents the first FDA clearance for a product with NIMBUS - an innovative technology so unique that it was put through the FDA's De Novo process, a special clearance program for medical devices that are found to be "not substantially equivalent" to any predicate device. Subsequent to its review of the data, the FDA has approved product labeling indicating various organisms such as MRSA, VRE, Pseudomonas aeruginosa and Escherichia coli are killed at levels exceeding 99.999%.(1) NIMBUS was a featured technology in TIME Magazine's 2006 Annual issue on innovation. The article, "Microbe-Busting Bandages", can be seen at the following url: http://www.time.com/time/magazine/article/0,9171,1172215,00.html.

Along with a superior rate of target-specific kill, what makes BIOGUARD different from other infection control dressings is the permanent, non-leaching bond between the dressing substrate and the active agent. The NIMBUS cationic biocide is permanently bonded to the gauze, keeping it from depleting in the presence of wound fluid and bacteria, while killing microbes that are drawn into the absorbent dressing. Active components that leach, such as silver and iodine-based dressings, currently make up the majority of the $200 million infection control dressings category in the US.

However, in today's environment of increasing bacterial resistance, creating new non-leaching alternative dressings is critical. According to Dr. Gregory Schultz, Ph.D., Professor, Institute for Wound Research at the University of Florida and Past President of the Wound Healing Society, since BIOGUARD is non-leaching, "it poses no risk of bacteria developing resistance, or of releasing toxic material into the wound and impeding the wound healing process. NIMBUS is a novel technology: bonded and effective even in high concentrations of body fluids."

Regarding surgical site infections and MRSA, the Centers for Disease Control and Prevention cite the following statistics:

  • There are over 500,000 surgical site infections in the US annually, accounting for one-quarter of all hospital acquired infections (2)

  • Two of the three most common procedures associated with MRSA infections are surgical treatment of skin/subcutaneous infection and the debridement of wound infection (3)

  • In 2005, researchers estimated there to be 94,360 invasive MRSA infections in the US. This amount is nearly triple the CDC 2001 estimate of 31,440 (4)

  • There is a 20% mortality rate associated with MRSA infections (5)

  • Deaths attributable to MRSA began to exceed deaths attributable to HIV/Aids in the US in 2005 (6)

      (1) Internal report, in vitro data.
      (2) Centers for Disease Control and Prevention, National Center for
          Health Statistics Vital and Health Statistics, Detailed diagnoses
          and procedures national hospital discharge survey 1994. Vol 127.
          Hyattsville (MD): Department of Health and Human Services; 1997.

      (3) Healthcare-Associated Methicillin Resistant Staphylococcus aureus
          (HA-MRSA). Centers for Disease Control and Prevention.
          www.cdc.gov/ncidod.
      (4) Fact Sheet: Invasive MRSA.  Centers for Disease Control and
          Prevention.  www.cdc.gov/ncidod.
      (5) MRSA: Methicillin-resistant Staphylococcus aureus in Healthcare
          Settings. Centers for Disease Control and Prevention.
          www.cdc.gov/features/MRSA.
      (6) Invasive Methicillin-Resistant Staphylococcus aureus Infections in
          the United States. A CDC Report. Journal of the American Medical
          Association. Oct 2007.

    Contact:

    Derma Sciences, Inc.
    Edward J. Quilty
    Chairman and CEO
    equilty@dermasciences.com
    (609) 514-4744

    Allen & Caron Inc
    Rudy Barrio (US Investors)
    r.barrio@allencaron.com
    (212) 691-8087

    Brian Kennedy (Media)
    brian@allencaron.com
    (212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting
2. Christian Diaz Joins Rodan + Fields(R) Dermatologists as Vice President of Sales
3. Galderma Launches New Cetaphil(R) SPF 50 Product
4. High and Super-High Potency Topical Corticosteroids Will Remain Decision Resources Clinical Gold Standard Through 2017 for the Treatment of Atopic Dermatitis
5. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
6. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
7. Direct Selling Luminary, Robert M. Henry, Partners With Rodan + Fields(R) Dermatologists as Strategic Business Advisor
8. New Source of Information on Scleroderma Medications
9. Dr. Sherrell Aston Addresses the Popularity of Dermal Fillers and Possible Long Term Side Effects
10. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
11. PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: